Biotechnology opened the door to new types of medicines based on nature’s own building blocks. No company has done more to advance this revolution than Amgen, and our broad toolkit of drug modalities just got larger.
Our product portfolio and clinical pipeline contain nine distinct modalities, and our drug discovery scientists are exploring four additional approaches, including two novel platforms added in 2016. Amgen Science’s latest feature provides an overview of these 13 tools, and how they can be applied to help patients facing serious illness.
Learn more about Amgen’s newest drug modalities on AmgenScience.com .